恒常性微质最初是种子,激活的微质后来在阿尔茨海默病中重塑了粉样质斑块
Nóra Baligács1,2, Giulia Albertini1,2, Sarah C Borrie1,2
1Centre for Brain and Disease Research, Flanders Institute for Biotechnology (VIB), Leuven, Belgium.
Nature communications
|December 5, 2024
概括
微质细胞在阿尔茨海默病 (AD) 中启动粉样质斑块的形成,这与一些观点相反. 它们的枯竭会减少斑块,但晚期可能会从它们的存在中受益,使AD治疗策略复杂化.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 病理学 病理学 病理学
背景情况:
- 微质在阿尔茨海默氏症 (AD) 粉样蛋白级联中的作用受到争议.
- 关于微质细胞对粉样β (Aβ) 斑块发育的直接影响,存在相互矛盾的发现.
研究的目的:
- 为了澄清微质在阿尔茨海默氏症中粉样蛋白病理的开始和进展中的精确作用.
- 调查微质枯竭和移植对Aβ斑块形成和相关神经毒性的影响.
主要方法:
- 在AD模型中利用基因和药理方法来研究微质枯竭.
- 采用微质移植研究来评估它们在Aβ斑块恢复中的作用.
- 分析了TREM2突变和适应性免疫衰竭对AD的微质功能的影响.
主要成果:
- 在Aβ沉积之前的小质枯竭减少了斑块数量和神经缩,证实了它们在斑块发作中的作用.
- 移植的人类微质细胞恢复了Aβ斑块的形成.
- 微质枯竭减少了不溶性Aβ,但不能溶性Aβ,挑战了清除理论.
- 在后期阶段,微质枯竭恶化了斑块紧缩和增加了神经缩,这表明它起到了保护作用.
- 人类微质中的TREM2R47H/R47H突变加剧了斑块病理.
结论:
- 微质细胞是阿尔茨海默病中启动粉样层级病理的关键驱动因素.
- 这些发现挑战了微质仅仅作为Aβ清除剂的概念,并暗示了复杂的,依赖阶段的作用.
- 对AD的最佳治疗策略可能需要考虑微质的双重作用,平衡启动和潜在的后期保护.
相关概念视频
Alzheimer's Disease: Overview
447
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
447
Amyloid Fibrils
9.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.2K
Alzheimer's Disease: Treatment
163
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
163


